RGC

U.S. Stock Market Midday Update

Regencell Bioscience fell 6.44%. Based on recent important news:

1. On June 17, Regencell Bioscience announced a 38-for-1 stock split, expanding the number of shares in circulation, which attracted retail investors and drove the stock price up. After the split, the stock price increased by 283.13%.

2. On June 17, Regencell Bioscience had not yet generated revenue from any product sales, and its core therapy needs to go through FDA Phase III clinical trials, with a failure probability as high as 80%, raising market concerns about its profitability.

3. On June 18, Regencell Bioscience had a very low float of only about 6%, causing the stock price to be highly volatile due to controlled capital movements.

Stocks with High Trading Volume in the Industry

Eli Lilly rose 0.50%, with increased trading volume. Based on recent important news:

1. On July 29, Eli Lilly announced that Mounjaro's new indication was approved in China, driving the stock price up by 0.50%.

2. On July 30, Novo Nordisk's stock price plummeted, affecting Eli Lilly, leading to a 5.59% drop in Eli Lilly's stock price.

3. On July 31, Mounjaro's trial results did not meet expectations, leading to a negative market reaction.

Novo Nordisk fell 3.31%, with increased trading volume. Based on recent important news:

1. On July 29, Novo Nordisk issued a profit warning and appointed a new CEO, causing the stock price to plummet by 23%, with a market value loss of $70 billion.

2. On July 30, analysts warned of intensified competition from generic drugs in the U.S. market, and Barclays downgraded its rating to neutral.

3. On July 31, HSBC downgraded Novo Nordisk's rating from buy to hold, with a target price lowered to $57.

Bristol-Myers Squibb fell 4.06%, with a trading volume of $1.013 billion. Based on recent important news:

1. On July 31, Bristol-Myers Squibb announced its second-quarter results, with net profit down 31%, but revenue exceeded expectations, leading to a pre-market stock price increase of 2%.

2. On July 29, Bristol-Myers Squibb and Bain Capital established a new company focused on developing therapies for autoimmune diseases, with a slight post-market stock price increase of 0.29%.

3. On July 31, analysts expected the full-year earnings per share to be below market expectations, putting pressure on the stock price.

Stocks with High Market Capitalization in the Industry

Johnson & Johnson fell 0.41%, with increased trading volume. Based on recent key news:

1. On July 29, Eli Lilly announced that its drug Jaypirca challenged Johnson & Johnson's Imbruvica in Phase III clinical trials, showing statistical advantages, putting pressure on Johnson & Johnson's stock price.

2. On July 30, Johnson & Johnson was ordered to pay $42 million in damages after a jury found that its talcum powder caused a man to develop cancer, increasing legal risks.

3. On July 29, Johnson & Johnson submitted a supplemental biologics license application; although there was positive progress, it failed to offset the impact of negative news